Introduction {#Sec1}
============

Esophageal cancer (EC) is one of the malignant tumors with a 5-year survival incidence of 20.9% \[[@CR1], [@CR2]\]. EC is ranked as the eighth most common malignant tumor with the sixth highest mortality rate worldwide. There are two histological subtypes of EC: esophageal squamous cell carcinoma (ESCC) and esophageal adeno carcinoma (EAC). ESCC often occurs in the top or middle of the esophagus, and starts in the flat thin cells that make up the lining of the esophagus. Meanwhile, EAC is most common in the lower portion of the esophagus, and starts in the glandular cells that are responsible for the production of fluids such as mucus. China is a high-risk area for EC, and more than 90% of cases are esophageal squamous cell carcinoma (ESCC) \[[@CR3]--[@CR5]\]. Moreover, most of the patients exhibit locally advanced or metastatic EC at the time of being diagnosed \[[@CR6], [@CR7]\]. Therefore, it is urgent to discover biomarkers for early clinical diagnosis to improve survival.

Esophageal cancer biomarkers have been found in saliva, blood, and urine. Sedighi et al. showed that the serum level of Matric metalloproteinase (MMP)-13 in ESCC patients were significantly higher than in the control group, and suggested that the MMP-13 was associated with increasing ESCC invasion, lymph node involvement and decreased survival rates \[[@CR8]\]. In saliva, the miRNAs (miR-10b\*, miR-144 and miR-451) were identified up-regulated expression in EC, which possessed discriminatory ability of detecting EC \[[@CR9]\]. Although these biomarkers contribute to the early diagnosis and prognosis of EC, the EC biomarker is still in the stage of exploration and verification, with limitations of specificity and low sensitivity.

Proteomic technologies have been applied to understand tumor pathogenesis, and to discover novel targets for cancer therapy or prognosis. Combining MS-based proteomic data with integrative bioinformatics can predict protein signal network and identify more clinical relevant molecules \[[@CR10]--[@CR12]\]. To date, quantitative proteomic methods have been applied in the study of various cancer, such as breast cancer, lung cancer, pancreatic cancer and gastric cancer \[[@CR13]\]. Mass spectrometric identification of differentially expressed proteins has been a highly successful approach for finding novel cancer-specific biomarkers \[[@CR14]\]. For more than a decade, attempts have been made to uncover valid biomarkers for the diagnosis of EC. Currently, various molecules have been identified as closely correlated with ESCC, such as transgelin (TAGLN) and proteasome activator 28-beta subunit (PA28β) \[[@CR15]\], pituitary tumor transforming gene (PTTG) \[[@CR6]\], transglutaminase 3 (TGM) by proteomics \[[@CR2]\]. However, the number of proteins identified was limited in these studies and they did not provide validation of the suggested biomarkers. Therefore, it is still necessary to perform further in-depth proteomics to explore novel candidate biomarkers for EC, and to validate the findings with orthogonal techniques.

Differential proteins obtained from mass spectrometry are commonly identified by Western Blot. However, it couldn't meet the requirements for high-throughput analysis, due to the complicated processing steps and the requirements for large amount of total protein. Recently, Quantitative Dot Blot (QDB) technology developed by our team achieves high-throughput quantitative detection with the same principle of traditional Western Blot. In addition, QDB technology has the advantages of less sample consumption, short time consumption and low cost \[[@CR16]\]. The experiment has been successfully applied to the detection of biomarker of papillary thyroid carcinoma. With its accuracy and reliability, the QDB is a very effective method for protein detection.

The aim of this study was to investigate the protein expression profiles in ESCC tissues and adjacent normal esophageal tissues with a label-free quantitative proteomics approach through nano-liquid chromatography coupled with tandem mass spectrometry (Nano-LC--MS/MS). The differentially expressed proteins were selected and their expression trends were validated in ESCC by Western Blot, then high-throughput protein screening was achieved by QDB, and the results of QDB were verified by classical IHC experiment. This research provides a new methodological strategy for validation and identification ESCC biomarkers by combining quantitative proteomic with QDB.

Materials and methods {#Sec2}
=====================

Tissue samples {#Sec3}
--------------

The five patients for LC/MS analysis were all male, with the average age of 61. Samples of ESCC tissues and adjacent normal esophageal tissues were taken for mass spectrometry analysis. The 64 pairs of matched ESCC and adjacent normal tissue samples for QDB were based on a clear pathological diagnosis, which included 35 men and 29 women, with an age range of 46--73 years (mean 61 years). The above samples were obtained at the Affiliated Yantai Hospital of Binzhou Medical University. All data were obtained from patient medical records. All specimens were quickly rinsed and then frozen immediately in liquid nitrogen and then stored at − 80 °C until further processing. The tissue microarrays (TMA) (ES701 and ES1922) for immunohistochemistry analysis were purchased from the alenabio company, the total sample size reached 117 pairs after removing duplicates in two arrays (n = 14). This study was approved by the Human Research Ethics Committee of Binzhou Medical University.

Reagents {#Sec4}
--------

Rabbit anti-PPP1CA (CSB-PA030161) and rabbit anti-PAK2 (CSB-PA622641DSR1HU) were purchased from CUSABIO (Wuhan, China). Rabbit anti-PTMA (YN2871) and rabbit anti-HMGB-2 (YT2187) were purchased from ImmunoWay Biotechnology Company (USA). The antibody of Caveolin (AF0126), Integrin beta-1 (AF5379), Collagen alpha-2(VI) (DF3552), Leiomodin-1 (DF12160) and Vinculin (AF5122) were purchased from Affinity Biosciences (USA). Mouse anti-GAPDH monoclonal antibody (sc-32233) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Goat anti-rabbit (127,760) and goat anti-mouse (124,227) secondary antibodies were purchased from ZSGB-BIO (Beijing, China).

Sample preparation {#Sec5}
------------------

The 5 pairs of clinical samples were homogenized and broken with lysis buffer containing 9 M Urea, 20 mM HEPES, and protease inhibitor cocktail. The samples were centrifuged at 12,000×*g* for 10 min at 4 °C and supernatants retained. Then 20 μg of total protein were digested using the way of in-solution digestion. Firstly, the samples were reduced with 50 mM dithiothreitol (DTT) at 50 °C for 15 min, then alkylated with 50 mM iodoacetamide (IAA) for 15 min in darkness, and then diluted 4 times with digestion buffer (50 mM NH~4~HCO~3~, pH 8.0). The proteins were digested by Trypsin with a final concentration of 5% (w/w), then incubated at 37 °C overnight. The reaction was stopped by diluting the sample 1:1 with trifluoroacetic acid (TFA) in acetonitrile (ACN) and Milli-Q water (1/5/94 v/v). Finally, peptides were desalted using Pierce C18 Spin Columns and dried completely in a vacuum centrifuge.

LC--MS/MS {#Sec6}
---------

The peptides were dissolved in 20 μL 0.5% TFA in 5% ACN and analyzed using QExactive Plus Orbitrap™ mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) coupled with the liquid chromatography system (EASY-nLC 1000, Thermo Fisher Scientific, Bremen, Germany). A 85-min LC gradient was applied, with a binary mobile phase system of buffer A (0.1% formic acid) and buffer B (80% acetonitrile with 0.1% formic acid) at a flow rate of 250 nL/min. In MS analysis, peptides were loaded onto the 2 cm EASY-column precolumn (1D 100 μm, 5 μm, C18, Thermo Fisher Scientific), and eluted at a 10 cm EASY-column analytical column (1D 75 μm, 3 μm, C18, Thermo Fisher Scientific). For information data dependent analysis (DDA), full scan MS spectra were executed in the m/z range 150--2000 at a resolution of 70,000. The peptides elution was performed with a linear gradient from 4 to 100% ACN at the speed 250 nL/min in 90 min. Then the top 10 precursors were dissociated into fragmentation spectra by high collision dissociation (HCD) in positive ion mode.

Proteomic data processing {#Sec7}
-------------------------

The acquired data were analyzed by using Maxquant (version 1.5.0.1) against the UniProt Homo sapiens database. The searching parameters were set as maximum 10 and 5 ppm error tolerance for the survey scan and MS/MS analysis, respectively. The enzyme was trypsin, and two missed cuts were allowed. The max number of modifications per peptide is 5. Using the Label-free quantification (LFQ), the LFQ minimum ratio count was set to 2. The FDR (false discovery rate) was set to 1% for the peptide spectrum matches (PSMs) and protein quantitation. Gene ontology and protein class analysis were performed with the PANTHER system (<http://pantherdb.org/>). Meanwhile, the heat map of significantly different proteins was screened by using Morpheus (<https://software.broadinstitute.org/morpheus>). The protein--protein interaction analysis of the differently expressed proteins was performed by STRING (<https://string-db.org/>).

Western blot (WB) {#Sec8}
-----------------

Tissues lysates were prepared by using highly efficient RIPA lysis buffer including PMSF (Phenylmethanesulfonyl fluoride). The total proteins were quantified by BCA protein assay kit and then separated by sodium dodesyl sulphate--polyacrylamide gel electrophoresis (SDS-PAGE). Equal amounts of protein were separated by 6%, 15% and 12% SDS-PAGE, respectively. Subsequently, proteins were transferred to a PVDF membrane and then blocked with TBS (pH 7.4) containing 0.05% Tween 20 and 5% nonfat milk. Next, the membranes were incubated with rabbit anti-PTMA (1:1000), rabbit anti-HMGB-2 (1:500), rabbit anti- PPP1CA (1:1000), rabbit anti-PAK2 (1:1000), and mouse anti-GAPDH (1:1000) antibodies at 4 °C overnight, respectively. The other five antibodies (Caveolin, Integrin beta-1, Collagen alpha-2(VI), Leiomodin-1 and Vinculin) were diluted in a ratio of 1:200. After washing, membranes were incubated with goat anti-rabbit (1:2000) and goat anti-mouse (1:2000) secondary antibodies at room temperature for 1 h. The ECL system was used to detect protein expression.

QDB {#Sec9}
---

The total proteins were quantified by BCA protein assay kit and then validated by Quantitative Dot Blot (QDB). Firstly, we determined the linear range of PTMA of the QDB analysis, through the testing of series of concentrations including 0, 0.25, 0.5, 1, 2 and 4 μg/μL. After that, equal amounts of protein were loaded. The sample was incubated at 37 °C for 15 min or until the membrane was completely dried. To block the plate, the QDB plate was dipped in 20% methanol. The plate was then washed with TBST, followed by 5% fat-free milk under constant shaking at room temperature for 1 h. After washing with TBST, the QDB plate was placed in a 96 well plate and 100 μL of primary antibodies was separately added to each individual well and shaken overnight at 4 °C. After washing the QDB plate, 100 μL of the secondary antibody was added to each well and incubated for 1 h at room temperature with shaking. Samples were washed with TBST and detected with the ECL substrate using a Tecan Infiniti 200 pro microplate reader. For each sample, a triplicate measurement was performed, and the average value was obtained. The relative quantitation of each PTMA protein in the lysates was then calculated.

Immunohistochemistry (IHC) {#Sec10}
--------------------------

The PTMA expression was detected by IHC in tissue microarrays (TMA) (ES701, ES1922). Firstly, the tissue microarrays were heated at 60 °C for 30 min, then deparaffinized and hydrated with xylol and gradient alcohol, respectively. Next, the antigen retrieval was accomplished by boiling the TMAs for 10 min in citrate buffer (0.01 M, pH 6.0). After cooling at room temperature, the microarrays were treated with 3% hydrogen peroxide for 30 min at 37 °C. The samples were blocked with bovine serum albumin for 30 min at 37 °C, then the PTMA antibody (YN2871, ImmunoWay; dilution 1:50) were incubated overnight at 4 °C in a moist chamber. After using the Histostain-SP (Streptavidin--Peroxidase) kit (SP-0023) as the secondary antibody following the recommendation from the manufacture, operation manual, the samples were washed with PBS (0.01 M, pH 7.2--7.4). Finally, the immunoreactivity was detected by DAB Horseradish Peroxidase Color Development Kit.

Statistics analysis {#Sec11}
-------------------

The WB data was analyzed by means and standard deviation for four independent experiments. The other data was compared between esophageal cancer tissues and adjacent normal esophageal tissues using the two-tailed paired Student's *t* test. All statistical analyses were performed by using the statistical software SPSS v20.0 (Chicago, Illinois, USA). *P* \< 0.05 was considered statistically significant.

Results {#Sec12}
=======

Identification of differently expressed proteins {#Sec13}
------------------------------------------------

The clinical information of the five patients was summarized in Table [1](#Tab1){ref-type="table"}. The five pairs of cancer tissues and adjacent normal tissues were analyzed by label-free mass spectrometry. Total 2297 proteins were identified and 308 proteins with significant differences were selected. Among these proteins, 102 proteins were expressed only in ESCC tissues (Table [2](#Tab2){ref-type="table"}), 155 proteins were significantly up-regulated (Table [3](#Tab3){ref-type="table"}) and 40 proteins were down-regulated in ESCC tissues (Table [4](#Tab4){ref-type="table"}) (*P* \< 0.05). Using the PANTHER classification system, we analyzed the biological significance of these proteins including the cellular component, molecular function and biological process (Fig. [1](#Fig1){ref-type="fig"}). The majority of proteins belonged to cell part proteins (37.3%) and organelle proteins (30.1%), possessed the ability of binding (41.8%) and catalytic activity (25.8%), and involved in the cellular process (29.6%), metabolic process (20.2%), cellular component organization or biogenesis (16.3%).Table 1The clinical features of ESCC patients for mass spectrometryNo.GenderAgeOrgan/anatomic siteGradeTNM1Male69Mid-thoracic esophagusIIT2N0MO2Male61esophagusIT1N0M03Male59Middle-lower esophagusIIT1N0M04Male52Mid-thoracic esophagusIIIT3N0M05Male64Middle segment of esophagusIIT2N1M1 Table 2List of 102 proteins that were uniquely identified in ESCC tissuesProtein IDsProtein namesP3005060S ribosomal protein L12P25788Proteasome subunit alpha type-3Q15254Prothymosin alphaP12956X-ray repair cross-complementing protein 6O15371Eukaryotic translation initiation factor 3 subunit DQ59FF0Staphylococcal nuclease domain-containing protein 1Q06323Proteasome activator complex subunit 1Q15366Poly(rC)-binding protein 2;Poly(rC)-binding protein 3Q99729Heterogeneous nuclear ribonucleoprotein A/BP6227340S ribosomal protein S29O15144Actin-related protein 2/3 complex subunit 2Q07955Serine/arginine-rich splicing factor 1Q13838Spliceosome RNA helicase DDX39BQ14666Keratin, type I cytoskeletal 17P00491Purine nucleoside phosphorylaseP13667Protein disulfide-isomerase A4P49755Transmembrane emp24 domain-containing protein 10P34932Heat shock 70 kDa protein 4P6275060S ribosomal protein L23aQ9BRL6Serine/arginine-rich splicing factor 2P26583High mobility group protein B2O60716Catenin delta-1Q13151Heterogeneous nuclear ribonucleoprotein A0P6224440S ribosomal protein S15aQ8TBK560S ribosomal protein L6P39656Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunitQ53GA7Tubulin alpha-1C chainQ92598Heat shock protein 105 kDaQ92928Ras-related protein Rab-1BQ59F66Probable ATP-dependent RNA helicase DDX17P4678240S ribosomal protein S5P78417Glutathione S-transferase omega-1P23526AdenosylhomocysteinaseP6208140S ribosomal protein S7P11413Glucose-6-phosphate 1-dehydrogenaseP67809Nuclease-sensitive element-binding protein 1Q08211ATP-dependent RNA helicase AP1798026S protease regulatory subunit 6AQ59EG826S proteasome non-ATPase regulatory subunit 2P27695DNA-(apurinic or apyrimidinic site) lyase, mitochondrialP61019Ras-related protein Rab-2AP28066Proteasome subunit alpha typeP49588Alanine--tRNA ligase, cytoplasmicO14818Proteasome subunit alpha typeQ8NB80Serine/arginine-rich splicing factor 7Q86UE4Protein LYRICP8373160S ribosomal protein L24B4DDM6Mitotic checkpoint protein BUB3P20618Proteasome subunit beta typeP31942Heterogeneous nuclear ribonucleoprotein H3Q13177Serine/threonine-protein kinase PAK 2P53621Coatomer subunit alpha;Xenin;ProxeninQ04760Lactoylglutathione lyaseQ99439Calponin;Calponin-2P6226640S ribosomal protein S23P6285740S ribosomal protein S28O43852CalumeninQ567R6Single-stranded DNA-binding proteinP22234Multifunctional protein ADE2P6219526S protease regulatory subunit 8P98179RNA-binding protein 3P4678140S ribosomal protein S9Q96FW1Ubiquitin thioesterase OTUB1O14979Heterogeneous nuclear ribonucleoprotein D-likeP51571Translocon-associated protein subunit deltaP05455Lupus La proteinQ96AE4Far upstream element-binding protein 1P17844Probable ATP-dependent RNA helicase DDX5P52597Heterogeneous nuclear ribonucleoprotein FP6086640S ribosomal protein S20Q13148TAR DNA-binding protein 43P62136Serine/threonine-protein phosphatase PP1-alpha catalytic subunitP07602ProsaposinP62633Cellular nucleic acid-binding proteinQ6FI03Ras GTPase-activating protein-binding protein 1P51572B-cell receptor-associated protein 31P2763560S ribosomal protein L10Q09028Histone-binding protein RBBP4Q9UMS4Pre-mRNA-processing factor 19P62318Small nuclear ribonucleoprotein Sm D3Q15056Eukaryotic translation initiation factor 4HP38159RNA-binding motif protein, X chromosomeQ1KMD3Heterogeneous nuclear ribonucleoprotein U-like protein 2P17987T-complex protein 1 subunit alphaQ13263Transcription intermediary factor 1-betaP29590Protein PMLQ92499ATP-dependent RNA helicase DDX1P51858Hepatoma-derived growth factorP60468Protein transport protein Sec61 subunit betaQ13185Chromobox protein homolog 3P55209Nucleosome assembly protein 1-like 1P50454Serpin H1P42704Leucine-rich PPR motif-containing protein, mitochondrialP61204ADP-ribosylation factor 1;ADP-ribosylation factor 3Q9HB71Calcyclin-binding proteinP11166Solute carrier family 2, facilitated glucose transporter member 1Q9Y265RuvB-like 1P62807Histone H2BQ9UK76Hematological and neurological expressed 1 proteinP12004Proliferating cell nuclear antigenP43243Matrin-3P6233326S protease regulatory subunit 10B Table 3List of 155 proteins that were overexpressed in ESCC tissuesIDsLog ratio*P* valueProtein namesP608427.8140.000Eukaryotic initiation factor 4A-IP233966.2770.00040S ribosomal protein S3P522727.6230.000Heterogeneous nuclear ribonucleoprotein MP4368610.1950.00026S protease regulatory subunit 6BP148668.8710.000Heterogeneous nuclear ribonucleoprotein LP536755.4840.001Clathrin heavy chain;Clathrin heavy chain 1P8409011.1710.001Enhancer of rudimentary homologP2239212.8810.001Nucleoside diphosphate kinaseQ011057.3300.001Protein SET;Protein SETSIPP841037.0840.001Serine/arginine-rich splicing factor 3P079009.4620.001Heat shock protein HSP 90-alphaQ015182.0760.001Adenylyl cyclase-associated proteinQ1523322.4890.001Non-POU domain-containing octamer-binding proteinP511497.2490.001Ras-related protein Rab-7aQ05CK99.7970.001Heterogeneous nuclear ribonucleoprotein QP108099.2350.00160 kDa heat shock protein, mitochondrialP683711.9350.001Tubulin beta-4B chainP378023.3330.001Transgelin-2P628266.9620.002GTP-binding nuclear protein RanP253984.8160.00240S ribosomal protein S12P577234.6110.002Poly(rC)-binding protein 1Q1290628.5770.002Interleukin enhancer-binding factor 3P088655.3090.00240S ribosomal protein SAP632446.2370.002Guanine nucleotide-binding protein subunit beta-2-like 1P1431414.5100.002Glucosidase 2 subunit betaP609009.1050.002Proteasome subunit alpha typeP0674812.7110.002NucleophosminP053888.0120.00260S acidic ribosomal protein P0P469403.5950.003Ras GTPase-activating-like protein IQGAP1P6197810.4440.003Heterogeneous nuclear ribonucleoprotein KP051412.8070.003ADP/ATP translocase 2Q6LDX713.0070.003Tyrosine-protein kinase receptorQ9962314.3810.003Prohibitin-2P067332.3610.003Alpha-enolaseP136395.4590.003Elongation factor 2Q1508443.3880.003Protein disulfide-isomerase A6Q96DV63.9440.00340S ribosomal protein S6Q66K539.6060.003HNRPA3 proteinP158804.5020.00340S ribosomal protein S2P390195.8980.00440S ribosomal protein S19P631042.0430.00414-3-3 protein zeta/deltaP226266.6380.004Heterogeneous nuclear ribonucleoproteins A2/B1P301016.0860.005Protein disulfide-isomeraseP257868.4200.005Proteasome subunit alpha type-1P1194012.4040.006Polyadenylate-binding proteinP164014.8770.006Histone H1.5P072375.7040.006Protein disulfide-isomeraseQ1677710.1600.006Histone H2A type 2-C;Histone H2A type 2-AP053865.8890.00660S acidic ribosomal protein P1P3194811.4910.006Stress-induced-phosphoprotein 1P319462.1560.00714-3-3 protein beta/alphaP681042.5580.007Elongation factor 1-alphaP003381.5900.007L-lactate dehydrogenaseQ141036.1890.007Heterogeneous nuclear ribonucleoprotein D0P3864610.6490.007Stress-70 protein, mitochondrialP2664119.7660.007Elongation factor 1-gammaO753474.1680.008Tubulin-specific chaperone AP094295.8780.008High mobility group protein B1P629427.4270.008Peptidyl-prolyl cis--trans isomerase FKBP1AQ9NUV17.2890.008Cytosolic non-specific dipeptidaseP110217.4670.00878 kDa glucose-regulated proteinP111422.3200.008Heat shock cognate 71 kDa proteinP025335.3200.008Keratin, type I cytoskeletal 14P300406.6570.008Endoplasmic reticulum resident protein 29P5099011.7130.008T-complex protein 1 subunit thetaP467839.5080.00840S ribosomal protein S10P3194314.0910.008Heterogeneous nuclear ribonucleoprotein HP1933813.6790.009NucleolinP1462513.1730.009EndoplasminQ925974.4640.009Protein NDRG1P2659919.5010.009Polypyrimidine tract-binding protein 1P683632.3170.009Tubulin alpha-1B chainP616049.7230.00910 kDa heat shock protein, mitochondrialP082388.9200.009Heat shock protein HSP 90-betaQ0083915.3380.009Heterogeneous nuclear ribonucleoprotein UP0484364.2750.009Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1P0965110.4890.010Heterogeneous nuclear ribonucleoprotein A1P223143.7580.010Ubiquitin-like modifier-activating enzyme 1P300853.1800.010UMP-CMP kinaseP2324639.0260.011Splicing factor, proline- and glutamine-richP2969213.7260.011Elongation factor 1-deltaP277977.5080.011CalreticulinQ068301.7880.011Peroxiredoxin-1P842432.5410.012Histone H3P0502315.3420.012Sodium/potassium-transporting ATPase subunit alpha-1Q149743.9950.014Importin subunit beta-1P301542.8820.014Serine/threonine-protein phosphatase 2AP494485.0130.015Glutamate dehydrogenaseP2070014.3790.015Lamin-B1P550726.0540.016Transitional endoplasmic reticulum ATPaseP355798.2780.016Myosin-9P402278.2410.016T-complex protein 1 subunit zetaP13010223.6280.017X-ray repair cross-complementing protein 5Q0325212.9190.017Lamin-B2P278249.1050.017CalnexinP025451.3760.017Prelamin-A/C;Lamin-A/CP6793610.1020.017Tropomyosin alpha-4 chainP049082.0180.018Histone H2AP137975.6840.019Plastin-3P529073.3770.019F-actin-capping protein subunit alpha-1P632414.1970.019Eukaryotic translation initiation factor 5AP624913.6280.019Ras-related protein Rab-11A;Ras-related protein Rab-11BP458802.3040.020Voltage-dependent anion-selective channel protein 2P053874.2570.02060S acidic ribosomal protein P2Q5SRT33.4840.021Chloride intracellular channel proteinP074373.6870.021Tubulin beta chainP232848.4010.022Peptidyl-prolyl cis--trans isomeraseP181245.4420.02260S ribosomal protein L7P073551.9090.022Annexin;Annexin A2P4677712.1240.02360S ribosomal protein L5Q997141.9230.0233-hydroxyacyl-CoA dehydrogenase type-2O755319.7450.024Barrier-to-autointegration factorQ1469721.1650.025Neutral alpha-glucosidase ABP622636.3470.02540S ribosomal protein S14P0DMV92.0490.026Heat shock 70 kDa protein 1BP290346.4580.026Protein S100-A2P628882.8930.02660S ribosomal protein L30Q6IBT323.3350.027T-complex protein 1 subunit etaP477562.8180.027F-actin-capping protein subunit betaP352227.5550.028Catenin beta-1P073395.9830.029Cathepsin DQ86SZ74.1510.029Proteasome activator complex subunit 2P153113.9030.029Ezrin;Tyrosine-protein kinase receptorP596654.5370.029Neutrophil defensin 1P099605.4920.030Leukotriene A-4 hydrolaseP632204.0480.03040S ribosomal protein S21Q16658114.9740.031FascinP079545.3990.032Fumarate hydratase, mitochondrialP548194.6520.034Adenylate kinase 2, mitochondrialP077371.2230.034Profilin-1P633135.2610.034Thymosin beta-10P217963.7160.034Voltage-dependent anion-selective channel protein 1P6124712.4490.03540S ribosomal protein S3aP146181.5080.035Pyruvate kinaseP616264.0290.036Lysozyme;Lysozyme CQ151818.4590.037Inorganic pyrophosphataseP273483.2200.03714-3-3 protein thetaP4941114.0690.037Elongation factor Tu, mitochondrialP0516410.0190.037MyeloperoxidaseP611605.9760.038Actin-related protein 2Q049174.7680.03914-3-3 protein etaP628051.7610.039Histone H4P263733.7000.04060S ribosomal protein L13Q142042.7990.041Cytoplasmic dynein 1 heavy chain 1P565377.5040.041Eukaryotic translation initiation factor 6P0870810.1440.04240S ribosomal protein S17P151532.6130.042Ras-related C3 botulinum toxin substrate 2P319492.1000.045Protein S100P369526.6790.046Serpin B5Q151494.6940.047PlectinP467796.1820.04860S ribosomal protein L28Q59FH05.4420.048Histone H2AP629371.7780.049Peptidyl-prolyl cis--trans isomeraseP077415.0770.049Adenine phosphoribosyltransferaseP622693.6880.05040S ribosomal protein S18 Table 4List of 40 proteins that were low-expressed in ESCC tissuesIDsLog ratio*P* valueProtein namesP552680.0780.001Laminin subunit beta-2Q133610.0000.001Microfibrillar-associated protein 5O956820.0000.001Tenascin-XP122770.0240.001Creatine kinase B-typeP207740.0180.002MimecanP063960.5010.002GelsolinO751060.0000.002Membrane primary amine oxidaseP606600.2600.002Myosin light polypeptide 6P518840.1180.003LumicanP355550.1830.003Fibrillin-1Q5U0D20.0810.004TransgelinP357490.0290.004Myosin-11P518880.0320.004ProlarginP248440.0330.005Myosin regulatory light polypeptide 9P176610.0630.005DesminP981600.2130.006Basement membrane-specific heparan sulfate proteoglycan core proteinP121090.2990.006Collagen alpha-1(VI) chainQ075070.0840.006DermatopontinP110470.2090.006Laminin subunit gamma-1Q6ZN400.1140.006CDNA FLJ16459 fisP182060.2590.008VinculinQ141120.0650.010Nidogen-2P212910.0860.011Cysteine and glycine-rich protein 1P680320.3120.011Actin, alpha cardiac muscle 1Q9NZN40.0000.012EH domain-containing protein 2P075850.0870.012DecorinQ157460.0210.014Myosin light chain kinase, smooth muscleQ9Y4900.3180.015Talin-1P121100.2230.016Collagen alpha-2(VI) chainP218100.2350.020BiglycanQ930520.0480.021Lipoma-preferred partnerP300860.5070.021Phosphatidylethanolamine-binding protein 1P627360.0430.022Actin, aortic smooth muscleQ96AC10.0290.023Fermitin family homolog 2Q6NZI20.2130.025Polymerase I and transcript release factorQ59F180.0000.027Smoothelin isoform b variantO145580.0000.027Heat shock protein beta-6Q136420.0040.028Four and a half LIM domains protein 1P121110.3210.031Collagen alpha-3(VI) chainP295360.0000.032Leiomodin-1P055560.4160.033Integrin beta-1Q151240.0000.033Phosphoglucomutase-like protein 5P213330.2130.033Filamin-AQ53GG50.0130.036PDZ and LIM domain protein 3P010090.4290.037Alpha-1-antitrypsin;Short peptide from AATP431210.0000.038Cell surface glycoprotein MUC18P529430.2100.041Cysteine-rich protein 2P082940.0000.043Extracellular superoxide dismutase \[Cu--Zn\]P565390.1550.043CaveolinO150610.0000.045SyneminQ9NR120.0440.047PDZ and LIM domain protein 7 Fig. 1Classification of identified proteins by gene ontology based on their **a** molecular function, **b** biological process and **c** cellular component. The analysis of proteins were performed via the PANTHER (<http://pantherdb.org/>)

Bioinformatics analysis of differentially expressed proteins {#Sec14}
------------------------------------------------------------

A volcano plot was generated based on the differential expression ratio and *P* value (Fig. [2](#Fig2){ref-type="fig"}a). Moreover, the heat map of significantly different proteins was shown in Fig. [2](#Fig2){ref-type="fig"}b by using Morpheus (<https://software.broadinstitute.org/morpheus>). Further protein--protein interaction analysis of the differently expressed proteins was performed by STRING, the result was shown in Fig. [3](#Fig3){ref-type="fig"}. Out of the four proteins selected for next analysis, the PPI network analysis revealed that PTMA was a valid target of c-myc transcriptional activation, while PPP1CA was involved in down-regulation of TGF-beta receptor signaling. PAK2 plays a role in apoptosis and activation of Rac, while HMGB2 is participating in chromatin regulation and retinoblastoma in cancer. Above mentioned, all these four proteins were associated with the occurrence and development of cancer. Bioinformatics analysis of the four genes from TCGA database revealed that the four genes up-regulated in gene level in EC tissue (Fig. [4](#Fig4){ref-type="fig"}). Whether these four genes can be used as biomarkers of esophageal cancer remains to be further studied.Fig. 2Analysis of protein differential expression. **a** Volcano plot graph illustrating the differential abundant proteins in the quantitative analysis. The − log10 (*P* value) was plotted against the log2 (ratio cancer/normal). The red dots represented proteins up-regulated in cancer samples, green dots corresponded to proteins down-regulated in cancer samples. **b** The heat map of significantly different proteins was shown between cancer tissues and adjacent normal tissues. The analysis was achieved by using Morpheus (<https://software.broadinstitute.org/morpheus>) Fig. 3Protein-protein interaction network of the differently expressed proteins was identified by STRING. Four proteins were selected for further study with filled red circles (<https://string-db.org/>) Fig. 4The expression of PTMA, PAK2, PPP1CA and HMGB2 in ESCC based on major cancer stages. In the TCGA databases, the four genes were up-regulated in EC patients (*P *\< 0.001). (<http://ualcan.path.uab.edu/analysis.html>)

Validation of differentially expressed proteins by Western Blot {#Sec15}
---------------------------------------------------------------

To further validate the LC--MS/MS results, we evaluated the four up-regulated proteins (PTMA, PAK2, PPP1CA, HMGB2) and the five down-regulated proteins \[Caveolin, Integrin beta-1, Collagen alpha-2(VI), Leiomodin-1 and Vinculin\] with Western Blot on the same samples. Compared with adjacent normal tissues, the protein expression of PTMA, PAK2, PPP1CA, HMGB2 were up-regulated (Fig. [5](#Fig5){ref-type="fig"}a, b), and the protein expression of Caveolin, Integrin beta-1, Collagen alpha-2(VI), Leiomodin-1, Vinculin were down-regulated in ESCC tissues from four pairs of samples (Fig. [5](#Fig5){ref-type="fig"}c, d). The results showed that the trends expression of these proteins were consistent with the LC--MS results.Fig. 5The differentially expressed proteins were validated by Western Blot. Compared with adjacent normal tissues, the protein expression of PTMA, PAK2, PPP1CA, HMGB2 were up-regulated (**a**, **b**), and the protein expression of Caveolin, Integrin beta-1, Collagen alpha-2(VI), Leiomodin-1, Vinculin were down-regulated in ESCC tissues from four pairs of samples (**c**, **d**). Representative immunoblot images (**a**, **c**) and histograms (mean ± SD; **b**, **d**).The experiments were repeated at least three times, N represented normal tissues and T represented tumor tissues

Validation of PTMA involved in ESCC by QDB and IHC {#Sec16}
--------------------------------------------------

In order to validate the proteins identified by mass spectrometric, the QDB technique was applied in a larger set of samples. We collected the samples of 64 patients, and the relevant clinical information was summarized in Table [5](#Tab5){ref-type="table"}. In the analysis of 64 patient samples, we found that 53 out of 64 esophageal cancer tissues showed higher PTMA expression than in the normal tissues (*P *\< 0.001) (Fig. [6](#Fig6){ref-type="fig"}). This trend was in accordance with the previous data. To further validate the QDB results, we performed the tissue microarray analysis by IHC. The results showed that among 117 pairs of tissues, the high expression rate of PTMA in tumor tissues was 98% (115/117). A significant overexpression of PTMA was found in tumor tissues in contrast to adjacent normal tissues (*P *\< 0.01) (Fig. [7](#Fig7){ref-type="fig"}). The sample information in the chip is summarized in Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}. We further evaluated the expression pattern of PTMA with the progression, and analyzed the PTMA expression trend in the different tumor Grades. The results revealed that the PTMA expression was up-regulated gradually along the progression of ESCC (Fig. [8](#Fig8){ref-type="fig"}). The PTMA expression ratio between tumor and adjacent normal tissue was significantly increased along with the progression (*P *\< 0.05). So we can suspect that PTMA might be participating in the development of esophageal cancer.Table 5The clinical features of ESCC patients for QDB analysisNo.GenderAgeOrgan/anatomic siteGradeTNM1Male69esophagusIIT1N0M02Male61esophagusIT0N0M03Male59esophagusIIT3N0M04Female65esophagusIT0N0M05Male52esophagusII--IIIT3N0M06Female73esophagusI--IIT1N0M07Male46esophagusIT0N0M08Male64Lower segment of esophagusIIT3N2M09Male57Mid-thoracic esophagusIIT3N0M010Male54Mid-thoracic esophagusII--IIIT3N0M011Male72Mid-thoracic esophagusIIT3N3M012Male66Mid-thoracic esophagusIIT3N3M013Male62Middle-lower esophagusIIT1N0M014Male60esophagusIIT3N0M015Female60esophagusIIT3N0M016Male64esophagusIIT3N0M017Female58Lower thoracic esophagusIIIT3N0M018Male53esophagusIIT3N0M019Male65Lower thoracic esophagusII--IIIT3N0M020Female60Mid-thoracic esophagusI--IIIT3N0M021Male69Middle-lower esophagusIIT3N3M022Female66esophagusII--IIIT3N2M023Female67Lower segment of esophagusII--IIIT3N3M124Male67Mid-thoracic esophagusIIIT3N1M025Female55Mid-thoracic esophagusIIT2N1M026Female61Mid-thoracic esophagusI--IIT1N2M027Male68esophagusII--IIIT3N2M028Female48Mid-thoracic esophagusI--IIT3N0M029Female63Mid-thoracic esophagusIIT1N1M030Male70Lower segment of esophagusIIT2N1M031Female59Mid-thoracic esophagusIIIT3N1M032Female48Mid-thoracic esophagusIIT3N0M033Female53Mid-thoracic esophagusIIT3N2M134Female58Lower thoracic esophagusI-IIT3N0M035Male62Mid-thoracic esophagusIIT2N0M036Female59esophagusIIT3N1M137Female57esophagusIIT3N0M038Female57Lower thoracic esophagusIIT3N1M139Female62Mid-thoracic esophagusI--IIT3N0M040Female69Mid-thoracic esophagusII--IIIT3N1M141Female61Mid-thoracic esophagusIIT3N2M142Female67Mid-thoracic esophagusIIT2N0M043Female47Mid-thoracic esophagusIIT2N0M044Female69Lower thoracic esophagusIIIT2N2M145Male66esophagusIIT3N0M046Male72Mid-thoracic esophagusIIT3N0M047Female69Mid-thoracic esophagusII--IIIT3N0M048Female73Mid-thoracic esophagusIT1N0M049Male62esophagusIIT3N0M050Male58esophagusIIT2N0M051Male56Lower segment of esophagusIIT1N0M052Male56Middle-lower esophagusIIT3N0M053Male56Middle-lower esophagusIIT3N0M054Male55esophagusI--IIT3N0M055Female61esophagusI--IIT3N0M056Female71Middle-lower esophagusI--IIT1N0M057Male61esophagusII--IIIT3N3M158Male62Upper thoracic esophagusIIIT3N0M059Male67Mid-thoracic esophagusIT1N0M060Male65esophagusIT3N0M061Male58esophagusII--IIIT2N1M162Male49Lower segment of esophagusIT1N0M063Female66esophagusIIIT3N1M164Male70esophagusIT1N0M0 Fig. 6The relative PTMA expression was tested by QDB in ESCC and adjacent normal tissues from 64 esophageal cancer patients. **a** The differential expression of PTMA was shown in each pair of tissues. **b** The PTMA expression was up-regulated in esophageal cancer tissues from the average of 64 pairs of tissues Fig. 7The relative PTMA expression was tested by IHC in ESCC and adjacent normal tissues among 117 pairs of tissues (× 200). **a** The expression of PTMA in adjacent normal tissues were presented. **b** The expression of PTMA in esophageal cancer were up-regulated. **c** The gray-scale analysis of immunohistochemical results (*P *\< 0.001) Table 6The 35 pairs samples in tissue microarrays (TMA) (ES701) for immunohistochemistry analysisNo.GenderAgeOrgan/anatomic siteGradeTNM1Male60EsophagusIIT3N1M02Male60Esophagus----3Male44EsophagusIT3N1M04Male44Esophagus----5Male50EsophagusIT3N2M06Male50Esophagus----7Male53EsophagusIT3N0M08Male53Esophagus----9Male64EsophagusIT3N1M010Male64Esophagus----11Male69EsophagusIT3N0M012Male69Esophagus----13Male59EsophagusIT3N0M014Male59Esophagus----15Male60EsophagusIT3N1M016Male60Esophagus----17Male72EsophagusIT3N1M018Male72Esophagus----19Female60EsophagusIT3N1M020Female60Esophagus----21Female75EsophagusIIIT3N0M022Female75Esophagus----23Male57EsophagusIIT3N1M024Male57Esophagus----25Female54EsophagusIIT3N1M026Female54Esophagus----27Male45EsophagusIIIT3N0M028Male45Esophagus----29Male52EsophagusIIT3N0M030Male52Esophagus----31Male68Esophagus--T3N0M032Male68Esophagus----33Male67EsophagusIT3N0M034Male67Esophagus----35Male55EsophagusIT3N0M036Male55Esophagus----37Male71EsophagusIT3N1M038Male71Esophagus----39Male63EsophagusIIIT3N1M040Male63Esophagus----41Male67EsophagusIIIT3N1M042Male67Esophagus----43Male57EsophagusIIIT3N0M044Male57Esophagus----45Male63EsophagusIIIT3N0M046Male63Esophagus----47Male57EsophagusIIIT3N1M048Male57Esophagus----49Male58EsophagusIIIT3N1M050Male58Esophagus----51Male53EsophagusIIT3N1M052Male53Esophagus----53Male49EsophagusIT3N1M054Male49Esophagus----55Male68EsophagusIIIT3N1M056Male68Esophagus----57Male48EsophagusIIIT3N0M058Male48Esophagus----59Female58EsophagusIIT3N1M060Female58Esophagus----61Male44EsophagusIIIT3N1M062Male44Esophagus----63Male63EsophagusIIT3N1M064Male63Esophagus----65Male68EsophagusIIIT3N1M066Male68Esophagus----67Female68EsophagusIIIT3N1M068Female68Esophagus----69Male62EsophagusIIIT2M1N1B70Male62Esophagus---- Table 7The 96 pairs samples in tissue microarrays (TMA) (ES1922) for immunohistochemistry analysisNo.GenderAgeOrgan/anatomic siteGradeTNM1Male58EsophagusIT3N0M02Male58Esophagus----3Male68EsophagusIT3N1M04Male68Esophagus----5Male52EsophagusIT1N0M06Male52Esophagus----7Female66EsophagusIT3N0M08Female66Esophagus----9Male72EsophagusIT3N1M010Male72Esophagus----11Male67EsophagusIT3N0M012Male67Esophagus----13Male66EsophagusIT3N1M014Male66Esophagus----15Male55EsophagusIT3N1M016Male55Esophagus----17Male67EsophagusIT3N1M018Male67Esophagus----19Female71EsophagusIT3N0M020Female71Esophagus----21Male69EsophagusIT3N0M022Male69Esophagus----23Male68EsophagusIT3N0M024Male68Esophagus----25Male44EsophagusIT3N1M026Male44Esophagus----27Female63EsophagusIT2N0M028Female63Esophagus----29Female54EsophagusIT3N1M030Female54Esophagus----31Male60EsophagusIT2N0M032Male60Esophagus----33Female68EsophagusIIT3N0M034Female68Esophagus----35Male49EsophagusIT3N1M036Male49Esophagus----37Male61EsophagusIT3N0M038Male61Esophagus----39Female69EsophagusIT3N1M040Female69Esophagus----41Male49EsophagusIT3N1M042Male49Esophagus----43Male68EsophagusIT3N0M044Male68Esophagus----45Male66EsophagusIIT3N0M046Male66Esophagus----47Male53EsophagusIIT3N1M048Male53Esophagus----49Female58EsophagusIT3N0M050Female58Esophagus----51Male63EsophagusIT3N0M052Male63Esophagus----53Female68EsophagusIT2N0M054Female68Esophagus----55Female68EsophagusIT3N0M056Female68Esophagus----57Male58EsophagusIT3N0M058Male58Esophagus----59Female60EsophagusIT3N0M060Female60Esophagus----61Male70EsophagusIIT2N1M062Male70Esophagus----63Female61EsophagusIT3N0M064Female61Esophagus----65Male54EsophagusIIT3N0M066Male54Esophagus----67Male45EsophagusIIT3N0M068Male45Esophagus----69Male75EsophagusIIIT3N0M070Male75Esophagus----71Male63EsophagusIT3N0M072Male63Esophagus----73Male68EsophagusIT3N0M074Male68Esophagus----75Female50EsophagusIIT3N0M076Female50Esophagus----77Male72EsophagusIIIT3N0M078Male72Esophagus----79Female53EsophagusIIIT3N0M080Female53Esophagus----81Male69EsophagusIIT3N1M082Male69Esophagus----83Male57EsophagusIT3N0M084Male57Esophagus----85Male68EsophagusIIIT3N1M086Male68Esophagus----87Male51EsophagusIIIT3N0M088Male51Esophagus----89Male70EsophagusIT3N1M090Male70Esophagus----91Male68EsophagusIIT3N1M092Male68Esophagus----93Male57EsophagusIIIT3N0M094Male57Esophagus----95Male48EsophagusIIT3N0M096Male48Esophagus----97Male63EsophagusIIIT3N1M098Male63Esophagus----99Male65EsophagusIIT3N0M0100Male65Esophagus----101Male71EsophagusIIIT3N1M0102Male71Esophagus----103Male78EsophagusIIIT3N0M0104Male78Esophagus----105Male53EsophagusIIT3N1M0106Male53Esophagus----107Male57EsophagusIIT3N0M0108Male57Esophagus----109Male63EsophagusIIT3N1M0110Male63Esophagus----111Male63EsophagusIIIT3N1M0112Male63Esophagus----113Female58EsophagusIT3N1M0114Female58Esophagus----115Male50EsophagusIIT2N0M0116Male50Esophagus----117Male44EsophagusIT3N1M0118Male44Esophagus----119Male61EsophagusIT3N1M0120Male61Esophagus----121Male61EsophagusIT3N1M0122Male61Esophagus----123Male57EsophagusIIT3N1M0124Male57Esophagus----125Male60EsophagusIT3N0M0126Male60Esophagus----127Male58EsophagusIIT3N0M0128Male58Esophagus----129Male61EsophagusIIT3N0M0130Male61Esophagus----131Male52EsophagusIT3N1M0132Male52Esophagus----133Female60EsophagusIIT3N1M0134Female60Esophagus----135Male68EsophagusIIT3N0M0136Male68Esophagus----137Female43EsophagusIIIT3N1M0138Female43Esophagus----139Male59EsophagusIIIT3N1M0140Male59Esophagus----141Male55EsophagusIIIT3N1M0142Male55Esophagus----143Male68EsophagusIIIT3N0M0144Male68Esophagus----145Female70EsophagusIIIT3N0M0146Female70Esophagus----147Male74EsophagusIIIT2N0M0148Male74Esophagus----149Male54EsophagusIT2N0M0150Male54Esophagus----151Male64EsophagusIIIT3N1M0152Male64Esophagus----153Male57EsophagusIT3N1M0154Male57Esophagus----155Male48EsophagusIIIT3N0M0156Male48Esophagus----157Female61EsophagusIIIT3N0M0158Female61Esophagus----159Male61EsophagusIIIT3N1M0160Male61Esophagus----161Male65EsophagusIIIT3N0M0162Male65Esophagus----163Male55EsophagusIIIT2N0M0164Male55Esophagus----165Female56EsophagusIIIT3N0M0166Female56Esophagus----167Female73EsophagusIIT3N0M0168Female73Esophagus----169Male70EsophagusIIIT3N0M0170Male70Esophagus----171Male53EsophagusIIIT3N1M0172Male53Esophagus----173Male67EsophagusIIIT2N0M0174Male67Esophagus----175Male69EsophagusIIIT3N0M0176Male69Esophagus----177Male68EsophagusIIIT3N0M0178Male68Esophagus----179Male64EsophagusIIIT3N0M0180Male64Esophagus----181Male61EsophagusIIIT3N1M0182Male61Esophagus----183Male59EsophagusIIIT3N0M0184Male59Esophagus----185Male57EsophagusIIIT2N0M0186Male57Esophagus----187Male64EsophagusIIIT3N0M0188Male64Esophagus----189Female67EsophagusIT2N0M0190Female67Esophagus----191Male47EsophagusIIIT2N0M0192Male47Esophagus---- Fig. 8The PTMA expression was up-regulated gradually along the progression of ESCC. **a** The PTMA expression trend at the different Grades in QDB samples. **b** The PTMA expression trend at the different Grades in IHC samples. I, II, III represented ESCC Grade I, Grade II and Grade III respectively. (\**P *\< 0.05)

Discussions {#Sec17}
===========

At present, most patients with esophageal cancer are diagnosed at the late and advanced stages \[[@CR17]\]. It is thus urgent to reveal biomarkers related to the progression of esophageal cancer for early diagnosis. Recently, several biomarkers were identified in EC detection, diagnosis, treatment and prognosis. For example, the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and estrogen receptor (ER) were important detection factors for immunohistochemistry in EC \[[@CR18]--[@CR20]\]. In blood, the serum p53 antibody had a potential diagnostic value for EC, however, the detection was limited by its low sensitivity \[[@CR21]\]. Therefore, we need to discover and verify more biomarker candidates for the prediction, diagnosis, treatment and prognosis of esophageal cancer.

Mass spectrometry is an effective method for finding distinct molecular regulators, between normal tissues and cancer tissues \[[@CR22]\]. In current study, we proposed a significant proteomics profiling difference including 308 proteins. However, compare to previous tissue-based ESCC proteomics study, a poor overlap of proteome profiling was noticed. There are several potential reasons. First, like many other cancers, ESCC is a heterogeneous cancer with different gene expression profiles from different populations \[[@CR23]\]. Recently, the whole-genome sequencing revealed the diverse models of structural variations in ESCC, which indicted the biological differences among patients \[[@CR24]\]. Therefore, the proteome variation may be a consequence of distinct molecular signatures that exist in ESCC. Another reasons could be related to the different experiment design, some of studies pooled several individual samples into a sample pooling, which would also lead to potential difference compare to our individual analysis \[[@CR25]\]. The difference of data analysis method would be another reason too, most of the labeled-based MS approach selected the expression fold change as the major criteria. In our study, with a label-free approach, we proposed paired Student's *t*-test significance as the main criteria. Such difference could lead to a different proteome profiling. The poor overlap indicated the importance of large-scale validation of biomarker. Thus we suggest in future studies, the proposed novel biomarker should be validated in a larger population no less than 100 samples. Besides TMA, our group recently developed QDB as a novel fast and accurate validation approach, which can easily validate biomarkers up to thousand samples \[[@CR16]\].

Human prothymosin-α (PTMA) is a 109 amino acid protein belonged to the α-thymosin family, which is ubiquitously distributed in mammalian blood, tissues and especially abundant in lymphoid cells. However, its role still remains elusive. The growing evidences suggested that PTMA being an important immune mediator as well as a biomarker might eventually become a new therapeutic target or diagnostic method in several diseases such as cancer and inflammation \[[@CR26]\]. So we focused on the possibility of PTMA as a biomarker of ESCC.

The proteomic studies show that PTMA exerts multifunction in nuclear and cytoplasmic. In proliferating cells, PTMA mainly locates in nuclear depending on the C-terminus signal sequence, but this protein can be transferred from the nucleus into the cytoplasmic during the cell extraction process \[[@CR27], [@CR28]\]. PTMA may mediate the chromatin activity by participated the nuclear-protein complex. In cytoplasmic, the function of PTMA is related to the state of phosphorylation, for example, the Thr7 is the only residue phosphorylated in carcinogenic lymphocytes while the Thr12 or Thr13 phosphorylated in normal lymphocytes \[[@CR29], [@CR30]\]. The co-immunoprecipitation experiments shows that PTMA interact with SET, ANP32A and ANP32B to form the complex, which is related to the cell proliferation, membrane trafficking, proteolytic processing and so on \[[@CR31]--[@CR33]\].

PTMA is known to play an important role in cell growth, proliferation, apoptosis and so on \[[@CR34], [@CR35]\]. Recent studies have confirmed that overexpression of PTMA is involved in the development of various malignancies, including colorectal, bladder, lung, and liver cancer \[[@CR36]--[@CR38]\]. In vivo tumorigenesis, the PTMA expression promotes the transplant tumor growth in mice and speeds up their death. Meanwhile, the PTMA interacts with TRIM21 directly to regulate the Nrf2 expression through p62/Keap1 signaling in human bladder cancer \[[@CR39]\]. In the patients with squamous cell carcinoma (SCC), adenosquamous cell carcinoma (ASC) and adenocarcinoma (AC) of the gallbladder, the positive expression of PTMA may be associated with the tumorigenesis, tumor progression and prognosis in gallbladder tumor. In addition, the high expression of PTMA may be as an indicator in the prevention and early diagnosis of gallbladder tumor \[[@CR40]\]. In addition to inducing cancer, Wang et al. discovered that PTMA as a new autoantigen regulated oral submucous fibroblast proliferation and extracellular matrix using human proteome microarray analysis. In addition, PTMA knockdown reversed TGFβ1-induced fibrosis process through reducing the protein levels of collagen I, α-SMA and MMP \[[@CR34]\]. However, there have been no evidences that PTMA participates in the pathogenesis of esophageal cancer.

Our mass spectrometry results showed that PTMA expression was up-regulated in ESCC tissues, and if the result was universal, it would provide a good biomarker for the diagnosis of ESCC. The traditional Western Blot is tedious, laborious and time-consuming for hundreds and thousands of large samples tests. In order to verify the results of mass spectrometry, we adopted the QDB technology invented recently, which was capable of high-throughput identification of target proteins from the perspective of biological experiments compared with Western Blot. QDB performed an affordable method for high-throughput immunoblot analysis and achieved relative or absolute quantification. In addition, the QDB needs less sample consumption, and the data can be conveniently read by a microplate reader. In HEK293 cells, the QDB successfully compared the levels of relative p65 levels between Luciferase and p65 clones in 71 pairs of samples. We have confirmed the accuracy and reliability of QDB from both cells and tissues \[[@CR16]\]. As above mentioned, QDB is a convenient, reliable and affordable method. In our study, we confirmed that 53 out of 64 tested ESCC tissues had higher PTMA expression by the QDB, and the results were identified by classical IHC methods in 117 pairs of samples.

In this study, we included both explore experiment and validation experiment, using early and late stage samples. The results from explore experiment indicated that PTMA was overexpressed in all stages. We further evaluated the expression pattern of PTMA with the progression, and analyzed the PTMA expression trend in the different Grades. The results revealed that the PTMA expression was up-regulated gradually along the progression of ESCC, and the PTMA expression ratio between tumor and adjacent normal tissue was significantly increased along with the progression. As it is almost impossible to obtain the extreme early stage (such as the stage without any symptom, or the stage prior to Grade I), but from the trend between Grade I and III, we can suspect the expression ratio of PTMA would be a potential indicator for the progression, even in the early diagnosis.

Conclusions {#Sec18}
===========

In our research, we used label-free quantitative proteomics to detect differentially expressed protein profiles in ESCC tissues compared to control tissues. In total 2297 proteins were identified and 308 proteins with significant differences were selected for study. Based on in-depth bioinformatic analysis, the four up-regulated proteins \[PTMA, PAK2, PPP1CA, HMGB2) and the five down-regulated proteins Caveolin, Integrin beta-1, Collagen alpha-2(VI), Leiomodin-1 and Vinculin\] were selected and validated in ESCC by Western Blot. Furthermore, we performed the QDB and IHC analysis in 64 patients and 117 patients, respectively. The PTMA expression was up-regulated gradually along the progression of ESCC, and the PTMA expression ratio between tumor and adjacent normal tissue was significantly increased along with the progression. Therefore, the PTMA is suggested as a candidate biomarker for ESCC. Our research also presents a new methodological strategy for the identification and validation of novel cancer biomarkers by combining quantitative proteomic with QDB.
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